PDS Biotech Reports Leadership/Compensation Changes

TL;DR

**PDS Biotech just announced executive changes, watch for strategic shifts.**

AI Summary

PDS Biotechnology Corp filed an 8-K on January 22, 2024, to report a "Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers." This filing indicates changes in the company's leadership or executive compensation, which could signal strategic shifts or new operational directions. For investors, these changes are important because new leadership often brings different strategies, potentially impacting the company's future performance and stock value.

Why It Matters

Changes in executive leadership or compensation can signal strategic shifts or new operational directions, directly impacting the company's future performance and stock valuation.

Risk Assessment

Risk Level: medium — While the filing indicates changes, the specific details of who departed or was appointed, and their compensation, are not provided in this summary, making the full impact unclear.

Analyst Insight

A smart investor would monitor PDS Biotechnology Corp's subsequent announcements for specific details regarding the leadership changes and compensation arrangements, as these will provide clearer insights into the company's strategic direction and potential impact on its stock.

Key Numbers

• $0.00033 — par value per share (par value of PDS Biotechnology Corp's Common Stock)

Key Players & Entities

• PDS Biotechnology Corp (company) — the registrant filing the 8-K
• January 22, 2024 (date) — date of earliest event reported and filing date
• Delaware (company) — state of incorporation for PDS Biotechnology Corp
• 001-37568 (dollar_amount) — Commission File Number
• 26-4231384 (dollar_amount) — I.R.S. Employer Identification No.
• 303A College Road East, Princeton, NJ 08540 (company) — address of Principal Executive Offices
• 800-208-3343 (dollar_amount) — Registrant’s Telephone Number
• PDSB (company) — Trading Symbol for Common Stock
• The Nasdaq Stock Market LLC (company) — exchange where Common Stock is registered

Forward-Looking Statements

• PDS Biotechnology Corp will announce specific details of leadership changes and compensation in a subsequent filing or press release. (PDS Biotechnology Corp) — high confidence, target: Q1 2024

FAQ

Key Financial Figures

• $0.00033 — ich registered Common Stock, par value $0.00033 per share PDSB The Nasdaq Stock Mar

Filing Documents

• ef20019392_8k.htm (8-K) — 30KB
• ef20019392_ex10-1.htm (EX-10.1) — 50KB
• ef20019392_ex99-1.htm (EX-99.1) — 18KB
• 0001140361-24-003165.txt ( ) — 252KB
• pdsb-20240122.xsd (EX-101.SCH) — 4KB
• pdsb-20240122_lab.xml (EX-101.LAB) — 22KB
• pdsb-20240122_pre.xml (EX-101.PRE) — 16KB
• ef20019392_8k_htm.xml (XML) — 4KB

02

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensation Arrangements of Certain Officers. Effective as of January 22, 2024, Lauren V. Wood, M.D. retired from her position as Chief Medical Officer of PDS Biotechnology Corporation (the "Company"). Dr. Wood's retirement is not related to any disagreement with the Company on any matter relating to the Company's operations, policies or practices. On January 22, 2024, the Company amended its 2019 Inducement Plan, as amended (the "Inducement Plan") solely to increase the total number of shares of the Company's Common Stock, par value $0.00033 per share, reserved for issuance under the Inducement Plan from 1,100,000 shares to 2,100,000 shares. The Inducement Plan, as amended, is filed as Exhibit 10.1 hereto and incorporated herein by reference. Item 7.01 Regulation FD Disclosure. On January 22, 2024, the Company issued a press release announcing the retirement of Lauren V. Wood, M.D. and the appointment of Kirk V. Shepard, M.D. as Chief Medical Officer of the Company, in each case, effective as of January 22, 2024. A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1. The information in this Item 7.01 and in Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference to such filing.

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 10.1 PDS Biotechnology Corporation 2019 Inducement Plan, as amended. 99.1 Press Release, dated January 22, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). Signature Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PDS BIOTECHNOLOGY CORPORATION By: /s/ Frank Bedu-Addo, Ph.D. Date: January 22, 2024 Name: Frank Bedu-Addo, Ph.D. Title: President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR